Daptomycin Market Research Report - Global Forecast till 2030

Daptomycin Market: By Indication (Complicated Skin Structure Infections, Bacteremia, others), Age Group (Pediatric, Adult), Strength (350mg, 500mg) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2030

ID: MRFR/HC/8603-HCR | 120 Pages | Published By Kinjoll Dey on March 2023         

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Daptomycin Market, by Indication

1.1.2. Global Daptomycin Market, by Age group

1.1.3. Global Daptomycin Market, by Strength

1.1.4. Global Daptomycin Market, by Region

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.3. Market Structure

3. RESEARCH METHODOLOGY

3.1. Research Process

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

3.5. Forecast Model

3.6. List of Assumptions

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.2.1. Increasing Complicated Skin & Skin Structure Infections

4.2.2. XXXXXX

4.2.3. XXXXXX

4.3. Restraints

4.3.1. XXXX

4.3.2. XXXX

4.4. Opportunities

4.4.1. Opportunity 1

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis/Supply Chain Analysis

5.2. Porter’s Five Forces Model

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. Impact Analysis of COVID-19 on Anatomic Pathology Market

5.3.1. Impact on Supply Chain

5.3.2. Impact on Pricing

5.3.3. Impact in Major regions (Americas, Europe, Asia-Pacific, Middle East & Africa)

6. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY INDICATION

6.1. Overview

6.2. Complicated Skin Structure Infections

6.3. Bacteremia

6.4. Others

7. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY AGE GROUP

7.1. Overview

7.2. Pediatric

7.3. Adult

8. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY STRENGTH

8.1. Overview

8.2. 350 mg

8.3. 500 mg

9. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY REGION

9.1. Overview

9.2. Americas

9.2.1. Market Estimates & Forecast, by Indication, 2022–2030

9.2.2. Market Estimates & Forecast, by Age group, 2022–2030

9.2.3. Market Estimates & Forecast, by Strength, 2022–2030

9.2.4. Market Estimates & Forecast, by Region, 2022–2030

9.2.4.1. North America

9.2.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.2.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.2.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.2.4.1.4. Market Estimates & Forecast, by Country, 2022–2030

9.2.4.1.4.1. US

9.2.4.1.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.2.4.1.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.2.4.1.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.2.4.1.4.2. Canada

9.2.4.1.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030

9.2.4.1.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030

9.2.4.1.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030

9.2.4.2. Latin America

9.2.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030

9.2.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030

9.2.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3. Europe

9.3.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4. Market Estimates & Forecast, by Region, 2022–2030

9.3.4.1. Western Europe

9.3.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4.1.4. Market Estimates & Forecast, by Country, 2022–2030

9.3.4.1.4.1. Germany

9.3.4.1.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4.1.4.2. France

9.3.4.1.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4.1.4.3. UK

9.3.4.1.4.3.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.4.3.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.4.3.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4.1.4.4. Italy

9.3.4.1.4.4.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.4.4.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.4.4.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4.1.4.5. Spain

9.3.4.1.4.5.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.4.5.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.4.5.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.4.1.4.6. Rest of Western Europe

9.3.4.1.4.6.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.4.1.4.6.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.4.1.4.6.3. Market Estimates & Forecast, by Strength, 2022–2030

9.3.5. Eastern Europe

9.3.5.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.3.5.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.3.5.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4. Asia-Pacific

9.4.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4.4. Market Estimates & Forecast, by Country, 2022–2030

9.4.4.1. China

9.4.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4.4.2. India

9.4.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4.4.3. Japan

9.4.4.3.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.4.3.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.4.3.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4.4.4. Australia

9.4.4.4.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.4.4.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.4.4.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4.4.5. South Korea

9.4.4.5.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.4.5.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.4.5.3. Market Estimates & Forecast, by Strength, 2022–2030

9.4.4.6. Rest of Asia-Pacific

9.4.4.6.1. Market Estimates & Forecast, by Indication, 2022–2030

9.4.4.6.2. Market Estimates & Forecast, by Age group, 2022–2030

9.4.4.6.3. Market Estimates & Forecast, by Strength, 2022–2030

9.5. Middle East & Africa

9.5.1. Market Estimates & Forecast, by Indication, 2022–2030

9.5.2. Market Estimates & Forecast, by Age group, 2022–2030

9.5.3. Market Estimates & Forecast, by Strength, 2022–2030

9.5.4. Market Estimates & Forecast, by Region, 2022–2030

9.5.4.1. Middle East

9.5.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030

9.5.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030

9.5.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030

9.5.4.2. Africa

9.5.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030

9.5.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030

9.5.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Daptomycin Market

10.5. Competitive Benchmarking

10.6. Leading Player in terms of Number of Developments in Global Daptomycin Market

10.7. Key Developments & Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisition

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2019

10.8.2. Major Players R&D Expenditure 2019

11. COMPANY PROFILES

11.1. Teva Pharmaceutical Industries Ltd.

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Indication Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Merck & Co.

11.3. Cipla

11.4. Pfizer

11.5. BE Pharmaceuticals

11.6. Dr. Reddy's Laboratories

11.7. Mylan

11.8. Fresenius Kabi

11.9. Nichi-Iko Pharmaceutical

11.10. Novo Holdings A/S

11.11. Zhejiang Hisun

11.12. Hengrui Medicine

11.13. Huadong Medicine

11.14. Civica Rx

12. APPENDIX

12.1. References

12.2. Related Reports

12.3. List of Abbreviation

NOTE:

This table of content is tentative and subject to change as the research progresses.

β€’ In section 11, only the top ten companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

β€’ Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.